Patricia M McGowan
Affiliation: University College Dublin
- ADAM-17: a novel therapeutic target for triple negative breast cancerP M McGowan
Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin, Ireland
Ann Oncol 24:362-9. 2013..e., those with triple-negative (TN) disease]. ADAM-17 is a protease involved in the activations of several ligands that bind to and promotes intracellular signalling from the EGFR/HER family of receptors...
- Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancerPatricia M McGowan
Department of Medical Biophysics, University of Western Ontario, London, Ontario, Canada
Mol Cancer Res 9:834-44. 2011..001; Kruskal-Wallis). These data suggest that the CSC phenotype contributes to the development of brain metastases from breast cancer, and this may arise in part from increased Notch activity...
- Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell linesAisling Pierce
Education and Research Centre, St Vincent s University Hospital, Dublin, Ireland
Cancer Biol Ther 14:537-45. 2013..e., whether HER2-positive, estrogen receptor (ER)-positive or triple-negative. Olaparib, in combination with a selective CDK1 inhibitor or a pan HER inhibitor, is a potential new approach for treating breast cancer...
- Role of ADAMs in cancer formation and progressionMichael J Duffy
Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, UCD School of Medicine and Medical Science, University College Dublin, Dublin, Ireland
Clin Cancer Res 15:1140-4. 2009..The ADAMs are thus a new family of potential targets for the treatment of cancer, especially malignancies that are dependent on human epidermal growth factor receptor ligands or tumor necrosis factor-alpha...
- Targeted therapy for triple-negative breast cancer: where are we?Michael J Duffy
UCD Clinical Research Centre, St Vincent s University Hospital, Dublin, Ireland
Int J Cancer 131:2471-7. 2012..The rational way forward for treating these patients is likely to be biomarker-driven, combination targeted therapies or combination of targeted therapy with cytotoxic chemotherapy...
- ADAM-17 expression in breast cancer correlates with variables of tumor progressionPatricia M McGowan
Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Ireland
Clin Cancer Res 13:2335-43. 2007..524, P < 0.0001, n = 73 and active form: r = 0.365, P = 0.002, n = 73). Our results support the hypothesis that ADAM-17 is involved in breast cancer progression...
- Micrometastatic disease and metastatic outgrowth: clinical issues and experimental approachesPatricia M McGowan
Department Medical Biophysics, University of Western Ontario, London, ON, Canada
Future Oncol 5:1083-98. 2009..Elucidation of the molecular pathways involved in dormancy will advance clinical understanding and may suggest new avenues for treatment to inhibit the revival of these dormant cells, thereby reducing cancer mortality rates...
- The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?Michael J Duffy
Department of Pathology and Laboratory Medicine, St, Vincent s University Hospital, Dublin 4, Ireland
Clin Proteomics 8:9. 2011..Furthermore, a number of selective ADAM inhibitors, especially against ADAM10 and ADAM17, have been shown to have anti-cancer effects. At least one of these inhibitors is now undergoing clinical trials in patients with breast cancer...
- The role of ADAMs in disease pathophysiologyMichael J Duffy
Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin 4, Ireland
Clin Chim Acta 403:31-6. 2009..Further work is required in order to establish a causative role for ADAMs in rheumatoid arthritis, Alzheimer's disease, cardiac hypertrophy and asthma...